1 ,,., ' lflie ~ Joli"' ~='

Fifth Annual San Diego Biotechnology /Biomedical Corporate Partnership Forum

"This Fomm has close to the optimal mix of large plwrmaceuticnl co1npanies, imxstors, and prese11ters from Sa11 Diego . I go to three or four partners/zip conferences a year; this one has closer ties with local i11dustry that you don't see in many regional conferences- that's T.uhy we're !Jere. You've really got some magic." James Gaylor, Ph.D., Corporate Director, '· Science and Technology Johnson & Johnson (Company participated in 1990, 1991 and 1992 Forums)

Thursday, November 4 and Friday, November 5, 1993 Hyatt Regency La Jolla, La Jolla, California

University of California, San Diego In association with: California Western School of Law Entrepreneurial Management Center, San Diego State University Foundation for International Scientific Advancement La Jolla Cancer Research Foundation La Jolla Institute for Allergy and Immunology The Preuss Foundation The Salk Institute The Scripps Research Institute The Whittier Institute

The UCSO Progm111 i11 Technology and Entrepreneurship , .. ~~~.,""~.... ~ ~ ~-,.:' :f!' CONNECTion ~,, .. ' -.. ,." "··" _ CS~~JY~CTing~witn

li.~!<""'~ ~·· ~ 1- ·1"}~~ -

In the five years since it was founded. the San Diego Biotechnology I The format of the program involves brief presentations from approximately two dozen companies "We haven't partici­ pated before, but it'll Biomedical Corporate Partnership Forum has developed a reputation on a wide range of biopharmaceutical and biomedical technologies; these companies are selected happen from now on." Martin Becker, Ph.D., for showcasing the most appropriate partnership opportunities with based on the understanding of the needs Senior Director of Biotechnology the best of San Diego and the region's emerging biotechnology compa- of prospective international pharmaceuti- Partnerships, Syntex Corporate Development (1992 Forum participant) nies. A two-day showcase of technology and partnership opportunities, cal, chemical and diagnostic company

the Forum is an opportunity to identifY strategic business alliances, as partners. Following the presentations,

well as learn about state-of-the-art drug discovery and development. It Forum attendees may sign-up for semi-

is also a chance to make new friends, reinforce existing relationships, private meetings with the principals of

and follow the progress of exciting companies on their way to developing new therapeutics, diag- these companies to ask more specific

nostics, and treatment or research procedures. questions.

Among the 75 international pharmaceutical, chemical, diagnostic and major biotechnology firms "Tizis is an absolutely wonderful conference. The format enabled me to have meaningful meetings with many companies." Ernst H. Schweizer, Dr.rer.nat., Chief Scientific and Technical Advisor, Ciba, Pharma Licensing (Company participated in 1991 and 1992 Forums) which attended last year's Forum were 16 of the top 19 pharmaceutical companies in the world,

demonstrating the value of this program to their companies. Corporate representatives involved in licensing or distribution relationships, business develop-

"While our division has specific technology interests, we have found ment, corporate development, new product planning, strategic planning, or other areas in which the San Diego Corporate Partnership Forum to be a productive way new p.artnership opportunities to leam about new tec/mologies, with both diagnostic and therapeutic "A company like ours applications, as well as track what's happening in leading-edge tech­ are being sought, should plan to is constantly looking nologies, wlzich may have further implications for our activities." for new teclznology to J. W. Burrus, Manager, Chemical Sales and Marketing, Abbott Laboratories attend the Forum. Participants ''The Corporate complement our (Company participated in 1991 and 1992 Forums) internal development Partnership Forum is will receive a Forum Notebook analogous to the drug efforts. The The consistent quality of the presenters is due to the screening that a Selection Committee, CONNECT Forum in development process. containing information on pre- San Diego is the best CONNECT does the composed of biotech business executives, patent and corporate counsel and other professional initial screening to senting companies, their tech- place to identifiJ tech- 1/ology complemen­ idwtify promising service providers, undertakes to select those companies with products or projects most likely to leads, and we evaluate nologies, management and part- tary to our efforts." the leads to see if they interest attendees of the Forum. Last Misao Ide, Ph.D., fit wit/z our tec/znolo­ nership opportunities. Managing Director, Research gy focus or internal year, the Forum featured such notable Laboratories abilities to develop (1992 Forum participant) them. If I had to companies as Prizm Pharmaceuticals, Plan to come to San Diego screen for these leads Sequel Therapeutics, Neurocrine November 4 & 5, 1993 to meet your colleagues and potential partners. on my own, it would take months, and Biosciences, Alanex Laboratories, Metra thousands of dollars "There were sonze companies here I hadn't heard of before- some new companies which I wouldn't other­ in travel expenses, to Biosystems and DepoTech Corporation. wise see. This Forum is such an efficient way of getting up-to-date on what's happening in San Diego that make the same I haven't missed one yet." number of contacts These companies met with an average David Leathers, Director, Abingworth Management Limited (1989, 1990, 1991 and 1992 Forum participant) t/zat I 111ake at this conference." of a dozen companies at the Forum, Bruce Riddell, Director, Market Planning, and have had multiple other contacts Ciba-Vision Ophthalmic~ (1992 Forum participant) since that time. The UCSD Progrmu in Technology nnd Entrepreneurship - .

_ .. :~~: .!.,~·-·~ ·';'. '· <-. •

'" ·.1,. ,J.o_• •

Previous Attendees of the San Diego BiotechnologyI Biomedical Corporate Partnership Forum

Abbott Diagnostics G.D. Sea rle & Co. Pierce Chemical Company Abbott Laboratories Gemini Science. Inc. Porlon Diagnostics Abingworth Management Limited Genentech Inc. PPG Industries Inc. Allergan Pharmaceuticals Gensia Pharmaceuticals Procter & Gamble Co. ALZA Corporation Genzyme R.W. Johnson Pharmaceutical AmeJican Cyanamid Company Glaxo. Inc. Recombinant Capital. Inc. AMGEN The Green Cross Corp. Recordati IndustJia Chemica Amoco Technology Company Hafslund Nycomed A.S. Ross Laboratm;es Anaquest Chemical Co., Ltd. S .C. Johnson & Son Inc. Armour Pharmaceutical Co. Hoechst Aktiengesellschaft S.R. One, Ltd. Bausch & Lomb Hoffmann-La Roche & Co. Salomon Brothers Venture Capital Beckman Instruments Hybritech Inc. Sandoz Pharmaceutical, Inc. Becton Dick:inson-ACB IG LaboratoJies Sanraku Inc. Bender +Co. GmbH Immunex Sankyo Co. , Ltd. Berlex Biosciences Institut MeJieux Ltd. BioCrysl Institute for Biological R&D Scandinavian Consulting Biometric Research Institute Institutional Venture Partners Schering-Plough Corp. BOC Group IOLAB SciClone Pharmaceuticals Bocknek J. T. America, Inc. SED Ventures S .A. Boehringer Ingelheim Pharm. Janssen Pharmaceutica Senmed Medical Boehringer Mannheim Corp. Johnson and Johnson Biot. Ctr. Sentron Medical Inc. Biistol-Myers/Squibb Co. Johnson and Johnson Sequoia Capital Burroughs Wellcome Co. Johnston Reuben Associates Servier C G F Pharmatech Inc. Kabi Pharmacia. Inc. Shin-Etsu Chemical Co. C. Itoh & Co. , Inc. Kaken Pharmaceutical Co. Ltd. Shionogi Research Laboratories Cambrtdge Quantum Fund Limited Kasho (USA) Inc. Specialty Maline Products, Ltd. Canadian Lysozyme Kleiner. Perkins, Caufield & Byers SRL Inc. Cell Technology Knoll Pharmaceuticals Sterling Winthrop Inc. Celltech Limited KnollAG Amelica. Inc. Chiron Kureha Chemical Industry Co. Syndel Laboratories. Ltd. Chugai Pharmaceuticals USA Kyokuto Pharma International Syntex Research Ciba Corning Diagnostics Corp. Kyowa Hakko Synthelabo Ciba-Geigy, Ltd. Lederle Laboratortes Synthetic Peptide Inc. Ciba-Vision Ophtahlmics Life Technologies Taiho Pharmaceutical Citec Manon Merrill Dow, Inc. Takeda Chemical Industries Connaught LaboratoJies, Inc. Mayfield Fund Tanabe Research LaboratoJies Corvas International McNeil Pharmaceuticals Teijen America, Inc. Cytodiagnostics Menlo Ventures Telios Pharmaceuticals Dainabot Co., Ltd. Mercian Corporation The Green Cross Corp. Dainippon Pharmaceutical Co. Merck & Co. Thomae GmbH/Boehringer Ingelheim Degussa Corporation Miles. Inc. Tokuyama Soda Co .. Ltd. Domain Associates Mitsubishi Kasei AmeJica Inc. Corp. Dupont Medical Products Dept. Miwon Co., Ltd. Toyobo Dupont-Merck Pharmaceutical Mochida Pharmaceuticals TRIGEN Inc. E. Merck Morgenthaler Ventures Trinity Ventures E.M. Warburg, Pincus & Co. Inc. Natural Products Sciences Inc. Triplex Pharmaceuticals Edinburgh Biomedical Newmarket Venture Capital PLC Triton Biosciences Eiken Chemical Co. Co .. Ltd. The Upjohn Company USA Inc. Norsk Hydro U.S. Venture Partners Eli Lilly and Co. Novo Nordisk A/S Vector SecuJities Enterplise Partners Ono Pharmaceuticals Von Gehr International Erbamont Ortho Biotech Warner-Lambert Company EuroCetus Parke-Davis/Warner-Lambert Co. Wyeth-Ayerst Research Ferring S .A. Pfizer Inc. Yarnanouchi Pharmaceutical Co. Funakoshi Co .. Ltd.

For more information. contact: CONNECT, UCSD Extension 0176 La Jolla, California 92093-0176 (619) 534-6114 Fax: (619) 552-0649